Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ
Список исп. литературыСкрыть список 1. Иванов С.В. Вальдоксан (агомелатин) при терапии умеренных и тяжелых депрессий непсихотического уровня в амбулаторной и госпитальной практике. Психиатр. и психофармакотер. 2009; 6: 15–9. 2. Иванов С.В. Вальдоксан в терапии биполярной депрессии: результаты российского многоцентрового натуралистического исследования ХРОНОС. Обозрение психиатрии и мед. психологии им. В.М.Бехтерева. 2011; 2: 26–30. 3. Смулевич А.Б., Андрющенко А.В., Бескова Д.А. Результаты исследования РИТМ: терапия непсихотической депрессии Вальдоксаном. Психиатр. и психофармакотер. 2010; 4: 4–12. 4. Тювина Н.А. Психические нарушения у женщин в период климактерия. М.: Крон-пресс, 1996. 5. Тювина Н.А., Смирнова В.Н. Сравнительная оценка агомелатина (Вальдоксана) при рекуррентной депрессии и биполярном аффективном расстройстве. Журн. неврол. и психиатр. им. С.С.Корсакова. 2012; 11: 53–60. 6. Aaronson S, Zuzarte E, Sklar J, Sklar M. Lamotrigine monotherapy with and without bupropion in the treatment of bipolar II depression. New Research Abstracts, Annual Meeting of the American Psychiatric Association. Washington DC. American Psychiatric Association 2008. 7. Agosti V, Stewart JW. Efficacy and safety of antidepressant monotherapy in the treatment of bipolar II depression. Int Clin Psychopharmacol 2007; 22: 309–11. 8. Akiskal HS, Pinto O. The evolving bipolar spectrum: prototypes I, II, III and IV. Psychiat Clin North Am 1999; 22: 517–34. 9. Akiskal HS. Dysthymia and cyclothymia in psychiatric practice a century after Kraepelin. J Affect Dis 2001; 62: 17–31. 10. Akiskal HS, Khani MK, Scott-Strauss A. Cyclothymic temperamental disorders. Psychiat Clin North Am 1979; 2: 527–54. 11. Alloy BL, Urošević S, Abramson LY et al. Progression along the bipolar spectrum: a longitudinal study of predictors of conversion from bipolar spectrum conditions to bipolar I and II disorders. J Abnorm Psychol 2012; 121 (1): 16–27. 12. Altshuler LL, Post RM, Leverich GS et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiat 1995; 152: 1130–8. 13. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorder. 4th ed. Text revision: DSM-IV-TR. Washington DC: American Psychiatric Publishing Inc 2000. 14. Amsterdam JD, Shults J. Comparison of short-term venlafaxine vs lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J Clin Psychopharmacol 2008; 28: 171–81. 15. Arnold LM. Gender differences in bipolar disorder. Psychiat Clin N Am 2003; 26 (3): 595–620. 16. Baldessarini R, Henk H, Sklar A et al. Psychotropic medications for patients with bipolar disorder in the US: polytherapy and adherence. Psychiat Serv 2008; 59: 1175–83. 17. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Dis 2007; 9 (6): 628–35. 18. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder. Bipolar Dis 2009; 11: 225–55. 19. Fountoulakis KN, Vieta E, Sanchez-Moreno J et al. Treatment guidelines for bipolar disorder: a critical review. J Affect Dis 2005; 86: 1–10. 20. Frances A, Docherty J, Kahn D. The expert consensus guideline series: treatment of bipolar disorder. J Clin Psychiat 1996; 57: 1–88. 21. Frances AJ, Kahn DA, Carpenter D et al. The expert consensus guidelines for treating depression in bipolar disorder. J Clin Psychiat 1998. 22. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003; 17: 149–73. 23. Grunze H. The clinical side of bipolar disorders. Pharmacopsychiat 2011; 44 (Suppl. 1): s43–8. 24. Joiner TE Jr, Steer RA, Beck AT et al. Physiological hyper arousal: construct validity of a central aspect of the tripartite model of depression and anxiety. J Abnorm Psychol 1999; 108 (2): 290–8. 25. Judd LL, Akiskal HS, Schlettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiat 2003; 60: 261–9. 26. Kawa I, Carter JD, Joyce PR et al. Gender differences in bipolar disorder: age at onset, course, comorbidity, and symptom presentation. Bipolar Dis 2005; 7 (2): 119–25. 27. McClung CA. Circadian genes, rhythms and the biology of mood disorders. Pharmacol Ther 2007; 114 (2): 222–32. 28. Mendlewicz J. Disruption of the circadian timing systems. Molecular mechanisms in mood disorders. CNS Drugs 2009; 23: 15–26. 29. Miguel L, Roncero C, López-Ortiz C, Casas M. Epidemiological and diagnostic axis I gender differences in dual diagnosis patients. Adicciones 2011; 23 (2): 165–72. 30. Parker G, Tully L, Olley A, Hadzi-Pavlovic D. SSRIs as mood stabilizers for bipolar II disorder? A proof of concept study. J Affect Dis 2006; 92: 205–14. 31. Riemann D, Voderholzer U. Primary insomnia: a risk factor to develop depression? J Affect Dis 2003; 76 (1–3): 255–9. 32. Sajatovic M, Valenstein M, Blow FC et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Dis 2006; 8: 232–1. 33. The ICD-10 classification of mental and behavioral disorders: clinical descriptions and diagnostic guidelines. World Health Organization. Geneva 1992. 34. Wehr TA, Sack DA, Rosenthal NE, Cowdry RW. Rapid cycling affective disorder: сontributing factors and treatment responses in 51 patients. Am J Psychiat 1988; 145: 179–84. 35. Yen CF, Cheng CP, Huang CF et al. Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission. Bipolar Dis 2008; 10: 617–24.